Feasibility and acceptability of the use of flash glucose monitoring encountered by Indigenous Australians with type 2 diabetes mellitus: initial experiences from a pilot study

BMC Health Serv Res. 2023 Dec 8;23(1):1377. doi: 10.1186/s12913-023-10121-6.

Abstract

Background: Type 2 diabetes mellitus (T2DM) is highly prevalent within the Indigenous Australian community. Novel glucose monitoring technology offers an accurate approach to glycaemic management, providing real-time information on glucose levels and trends. The acceptability and feasibilility of this technology in Indigenous Australians with T2DM has not been investigated.

Objective: This feasibility phenomenological study aims to understand the experiences of Indigenous Australians with T2DM using flash glucose monitoring (FGM).

Methods: Indigenous Australians with T2DM receiving injectable therapy (n = 8) who used FGM (Abbott Freestyle Libre) for 6-months, as part of a clinical trial, participated in semi-structured interviews. Thematic analysis of the interviews was performed using NVivo12 Plus qualitative data analysis software (QSR International).

Results: Six major themes emerged: 1) FGM was highly acceptable to the individual; 2) FGM's convenience was its biggest benefit; 3) data from FGM was a tool to modify lifestyle choices; 4) FGM needed to be complemented with health professional support; 5) FGM can be a tool to engage communities in diabetes management; and 6) cost of the device is a barrier to future use.

Conclusions: Indigenous Australians with T2DM had positive experiences with FGM. This study highlights future steps to ensure likelihood of FGM is acceptable and effective within the wider Indigenous Australian community.

Keywords: Aboriginal people; Flash glucose monitoring; Indigenous Australian; Phenomenological study; Qualitative research; Type 2 diabetes mellitus.

MeSH terms

  • Australia
  • Australian Aboriginal and Torres Strait Islander Peoples
  • Blood Glucose / analysis
  • Blood Glucose Self-Monitoring* / methods
  • Diabetes Mellitus, Type 2* / therapy
  • Feasibility Studies
  • Humans
  • Pilot Projects

Substances

  • Blood Glucose